B1

1. (Twice Amended) A fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising: a podophyllotoxin selected from the group consisting of etoposide and teniposide, and tocoferol covalently linked to a water-soluble polymer; with the proviso that free tocoferol is not present.

B2

10. (Twice Amended) The fluid pharmaceutical composition of claim 1 wherein the tocoferol covalently linked to a water-soluble polymer is d-α-tocopheryl polyethylene glycol 1000 succinate or a derivative thereof.

B3

18. (Twice Amended) A method of treating an animal comprising administering to the animal a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

> a podophyllotoxin selected from the group consisting of etoposide and teniposide, and tocoferol covalently linked to a water-soluble polymer; with the proviso that free tocoferol is not present.

19. (Twice Amended) The method of claim 18 wherein the tocoferol covalently linked to a water-soluble polymer is d-α-tocopheryl polyethylene glycol 1000 succinate or a derivative thereof.

20. (Twice Amended) A method of delivering a podophyllotoxin selected from the group consisting of etoposide and teniposide to a cell comprising administering to the cell a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

> a podophyllotoxin selected from the group consisting of etoposide and teniposide; and tocoferol covalently linked to a water-soluble polymer; with the proviso that free tocoferol is not present.

21. (Twice Amended) A method of inhibiting cancer comprising administering to an animal having cancer a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising: